Skip to content

Role of Multiplex PCR in CAP

Molecular Methods for Identifying Bacteria in Lower Respiratory Tract Specimens Among Patients With Pneumonia by Multiplex PCR

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06097117
Enrollment
66
Registered
2023-10-24
Start date
2023-11-01
Completion date
2024-12-01
Last updated
2023-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired Pneumonia

Brief summary

1. role of multiplex PCR in early identifying bacteria in patients with lower respiratory tract infection. 2. effect of early starting targeted antibiotics on outcome

Detailed description

Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality. Identification of microbial pathogens which cause pneumonia is an important area for optimum clinical management of pneumonia patients and is a big challenge for conventional microbiological methods. The development and implementation of molecular diagnostic tests for pneumonia has been a major advance in the microbiological diagnosis of respiratory pathogens in recent years. Targeted antibiotic selection and more effective de-escalation and improved stewardship for pneumonia patients. PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay. Each PCR assay requires the presence of template DNA, primers, nucleotides, and DNA polymerase .The DNA polymerase is the key enzyme that links individual nucleotides together to form the PCR product. The nucleotides include the four bases - adenine, thymine, cytosine, and guanine (A, T, C, G) - that are found in DNA. These act as the building blocks that are used by the DNA polymerase to create the resultant PCR product. The primers in the reaction specify the exact DNA product to be amplified. The primers are short DNA fragments with a defined sequence complementary to the target DNA that is to be detected and amplified. These serve as an extension point for the DNA polymerase to build on.There are multiple advantages to PCR. First, it is a simple technique to understand and to use, a nd it produces results rapidly. It is a highly sensitive technique with the potential to produce millions to billions of copies of a specific product for sequencing, cloning, and analysis. Although PCR is a valuable technique, it does have limitations. Because PCR is a highly sensitive technique, any form of contamination of the sample by even trace amounts of DNA can produce misleading results . In addition, in order to design primers for PCR, some prior sequence data is needed. Therefore, PCR can only be used to identify the presence or absence of a known pathogen or gene

Interventions

DIAGNOSTIC_TESTMultiplexPCR

PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* male and female * Age \>18 years Old Adult patients were included if they fulfilled: * radiographic and clinical criteria. * Radiographic findings included chest imaging with an airspace opacity, lobar consolida-tion, or interstitial opacities * new or worsening compared to available baseline. In addition, at least 2 of the following clinical criteria had to be fulfilled: 1. reported or documented fever \> 37.5 2. new worsening productive cough or increase in respiratory secretions in intubated patients 3. pleuritic chest pain 4) new/worsening dyspnea or hypoxia, defined as documented blood oxygen saturation \<92%.

Exclusion criteria

Patients under 18 years old. Patients who refuse to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
detect Antimicrobial therapy duration in CAP in comparison in both groups1 yearAntimicrobial therapy duration in patients with CAP in comparison of two groups
detect clinical improvement in both groups1 yeardetection of clinical improvement in both groups (subsided of bronchial symptoms as productive cough ,colored sputum, relieve of dysnea and pleuritic chest pain , subsided of fever

Contacts

Primary ContactAsmaa Saleh Mousa, resident physician
asmaa241.saleh@gmail.com01149227845
Backup ContactLamia Hasan Shaaban, prof
Lamiashaban@yahoo.com01002681478

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026